Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Galenica reports 5.7% sales growth in nine months and confirms annual target

Galenica increased sales from January to September by 5.7% to CHF 3.17 billion, driven by the pharmacy business, Home Care and the newly built Diagnostics division. The Products & Care segment grew by 10.9% thanks to strong demand for GLP‑1 preparations and rheumatology drugs, while Logistics & IT rose by only 2.7% and lagged expectations. Analyst expectations were missed overall, but the company confirmed its full-year targets of +5–7% sales growth and +6–8% adjusted operating profit, and a dividend at least at last year’s level. After the IT switchover at Galexis, management expects stronger momentum in the final quarter. » More on finanzen.net
Galenica meets growth targets in first half and confirms full-year targets

Galenica increased revenue in the first half by 7.1% to CHF 2.14 billion and adjusted EBIT by 7.1% to just under CHF 118 million; net profit was around CHF 92 million (+1.3%). Drivers were the pharmacy business and wholesale, particularly the Products & Care segment (+11.5%) thanks to strong demand for GLP‑1 preparations, and the Diagnostics business following the acquisition of Labor Team. The Logistics & IT segment grew by 4.2% and Galenica gained market share in the pharmacy channel. For 2026 the company confirms its targets: revenue growth of 5–7%, adjusted operating result +6–8% and at least an unchanged dividend; expected one-off costs for the closure of the Bichsel production unit were estimated at around CHF 30 million. » More on finanzen.net
Galenica continues growth in 2026 and confirms targets

Galenica continues its growth trajectory in 2026 and confirms the targets set for the year. The company reports continued growth in the new fiscal year. » More on finanzen.net
Galenica reduces staff cuts at subsidiary Bichsel in Interlaken

Galenica will lay off fewer employees at its Interlaken subsidiary Bichsel than originally planned. The adjustment reduces the scale of the local workforce reduction; no further details on the number of positions affected were given. » More on finanzen.net
Galenica increases adjusted EBIT by 11% and raises dividend to CHF 2.50

Galenica reports 2025 net sales of CHF 4.136 billion (+5.5%) and adjusted EBIT of CHF 234.8 million (+11.3%). The board proposes an 8.7% dividend increase to CHF 2.50. The acquisition of Labor Team drove investments and net debt to CHF 675 million (2.3x EBITDA), while operating cash flow and free cash flow before M&A rose significantly. For 2026 Galenica expects revenue growth of 5–7% and adjusted EBIT growth of 6–8% (9–11% excluding special items). » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Galenica has already paid €2.72 in dividends. The last payout was in April.

Financials

In the last quarter, Galenica had revenue of €2.31B and net profit of €71.88M

(EUR)	June 2026	YoY
Revenue	2.31B	-
Gross profit	210.04M	-
Net profit	71.88M	-
EBITDA	180.7M	-

Fundamentals

Metric	Value
Market capitalization	€4.85B
Number of shares	49.82M
52-week high/low	€111.49 - €87.08
Dividend yield	2.77%
Dividends TTM	€2.72
Beta	0.29
P/E ratio	28.31
PEG ratio	-1.63
P/B ratio	3.19
P/S ratio	1.05

Company profile

Galenica AG operates as a healthcare service provider in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates 520 pharmacies, including 368 owned pharmacies and 152 partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands. This segment also offers medication for treatment of patients at home; launches and distributes a portfolio of consumer health, pharmaceutical, and parapharmaceutical products; and marketing and sale services to partners in the healthcare market. The Logistics & IT segment provides range of specialized pre-wholesale services, including storage, distribution, and debt collection to pharmaceutical and healthcare companies. This segment also offers logistics and IT services, and master data system for the healthcare market; develops management solutions for the healthcare market; and publishes printed and electronic technical information on pharmaceutical products, as well as complete management solutions for pharmacies. The company was founded in 1927 and is headquartered in Bern, Switzerland.